Latest Malaysia News

OM Holdings reversed a loss to report a US$26.3 million profit in 1H 2026, driven by a major asset disposal and improved product margins despite lower sales volumes.

UOA Development Bhd reported a 70% rise in quarterly revenue to RM221.2 million and a modest profit increase to RM95.6 million, driven by ongoing projects and robust new property sales.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

EVZ Limited reported a 14% revenue increase to $123.1 million and a 213% jump in net profit after tax to $3.87 million for FY2026, resuming dividends for the first time since 2010.

DXN Limited has landed a A$12.2 million contract to deliver a 2MW AI High-Performance Computing modular data centre, expanding its AI HPC order book to about A$21 million and positioning the company for further growth in a booming market.

Ovanti Limited has launched a 1-for-1 entitlement offer to raise approximately AUD 2.293 million at 0.2 cents per share, targeting working capital and offer costs. The offer closes on 1 September 2026 and includes a top-up facility for additional shares.

IDP Education’s FY26 results reveal a sharp 75% plunge in net profit as student volumes shrink, but the company pushes ahead with a $32 million cost-cutting transformation and AI investments.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Whitehaven Coal reported a 29% drop in underlying net profit to $227 million for FY26, despite record safety outcomes and successful debt refinancing that lowered funding costs and extended maturities.

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Ovanti Limited is raising up to A$2.293 million through a 1-for-1 entitlement offer priced at $0.002 per share, marking a significant capital boost at a notable discount to recent trading.